Radiopharm Theranostics(RDPTF)

Focus: Radiopharm Theranostics is a publicly listed Australian biotech company focused on radiopharmaceutical therapeutics, currently operating at micro-cap scale with 1-50 employees.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

1-50

Open Jobs

About Radiopharm Theranostics

AI assessmentNot Hiring

No open roles listed right now. Follow Radiopharm Theranostics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

177Lu-RAD202

HER2 Gene Mutation

Phase 1

Clinical Trials (1)

NCT06824155HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

Phase 1

Help build intelligence for Radiopharm Theranostics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in high-growth radiopharmaceutical space with 7 active clinical programs spanning oncology and neurology
Public company status provides liquidity and transparency rare for early-stage radiopharm developers
Rare exposure to emerging isotope modalities (177Lu, 161Tb) with potential for significant first-mover advantage in theranostic space

Watch Out For

Zero open positions and micro-scale team (1-50 employees) indicates minimal hiring activity and limited career infrastructure
No disclosed revenue, financials, or funding data raises questions about cash runway and ability to fund clinical progression
All programs in Phase 1-2 with no Phase 3 data or near-term regulatory catalysts; path to approval likely 5+ years away

Generated by Claude from Radiopharm Theranostics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RAD301

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05799274Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Phase 1

LNTH-2403

Imaging

Phase 1

Clinical Trials (1)

NCT07272642A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.

Phase 1